Last reviewed 2026-04-20 · How we verify

AZD6738 (azd6738)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Dyspnoea
• Fatigue
• Anaemia
• Cough
• Nausea
• Influenza
• Diarrhoea
• Decreased appetite
• Pain in extremity
• Rash
• Vomiting
• Pleural effusion

Key clinical trials

• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
• Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer (PHASE3)
• Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) (PHASE2)
• Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (PHASE2)
• A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours (PHASE1)
• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (PHASE2)
• AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
• Olaparib With Ceralasertib in Recurrent Osteosarcoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AZD6738 CI brief — competitive landscape report
• AZD6738 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI